Literature DB >> 3105236

Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?

S S Pedersen, T Jensen, T Pressler, N Høiby, K Rosendal.   

Abstract

Two hundred and forty Danish patients with cystic fibrosis (97% of the total CF population in Denmark) participated in a point-prevalence study of Pseudomonas aeruginosa infection. One hundred and ninety-two patients were treated at the Danish CF centre and 48 patients were treated in other places. The age distribution was significantly different as no patients older than 19 years were found in the non-centre group. Pathogenic bacteria were isolated from the sputum of 96% of the patients. P. aeruginosa was more prevalent in patients from the centre, whereas Staphylococcus aureus was more prevalent in the non-centre group. No difference in serogroup and phage pattern of P. aeruginosa was found. There was a tendency that non-centre treated patients acquired chronic broncho-pulmonary P. aeruginosa infection later, but at the age of 16 years 90% of all patients will be chronically infected. Chronic P. aeruginosa infection was significantly more common in the age group 10-14 years at the centre than outside the centre. It is not possible to prevent chronic P. aeruginosa infection in CF patients treated in small groups and because of the better prognosis of centralized treatment the latter must be recommended.

Entities:  

Mesh:

Year:  1986        PMID: 3105236     DOI: 10.1111/j.1651-2227.1986.tb10299.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  18 in total

1.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

2.  Comparison of ribotyping and genome fingerprinting of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  T Bennekov; H Colding; B Ojeniyi; M W Bentzon; N Høiby
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

3.  Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; T Jensen
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

Review 4.  Management of the chest in cystic fibrosis.

Authors:  B M Phillips; T J David
Journal:  J R Soc Med       Date:  1987       Impact factor: 5.344

5.  Pseudomonas aeruginosa and cystic fibrosis: Antibiotic therapy and the science behind the magic.

Authors:  N E Macdonald
Journal:  Can J Infect Dis       Date:  1997-11

6.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

7.  Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

Authors:  T Jensen; S S Pedersen; N Høiby; C Koch
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

Review 8.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

Review 9.  The relationship between atopy and cystic fibrosis.

Authors:  R W Wilmott
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 10.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.